Blood thinner levels in ICU patients with kidney failure
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study looks at how a common blood thinner (enoxaparin) is processed in the body of ICU patients with kidney failure, including those on dialysis. The goal is to make sure the dose is safe and effective for preventing blood clots in this fragile group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are in the intensive care unit (ICU) and need a daily blood thinner injection to prevent blood clots.
- You either have severe kidney problems (with or without dialysis) or you have normal kidney function as part of a comparison group.
- Your weight is between 50 and 120 kg (about 110 to 264 pounds).
- You have not recently taken certain blood thinners (like apixaban, rivaroxaban, or dabigatran) in the last 3 days, and no low-molecular-weight heparin (like enoxaparin) in the last 24 hours.
- You do not have a high risk of bleeding, a known bleeding disorder, or severe liver disease (Child Pugh C).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a blood-thinning medication (heparin) to critically ill patients with serious kidney problems to see if it safely prevents blood clots. It may help reduce the risk of clots without raising bleeding risk in this vulnerable group.
This study compares two doses of a blood thinner (enoxaparin) to see which better prevents blood clots in patients with severe injuries who are in the intensive care unit. It helps doctors choose the best dose to keep you safe and healthy.
This study looks at whether a blood test measuring a substance called anti-factor Xa activity can help predict dangerous blood clots in critically ill patients. If you join, researchers will follow you to see if the test results can prevent clots.
This trial tests whether a daily injection of a blood-thinning medicine called enoxaparin (Lovenox) can safely prevent dangerous blood clots in teens who are critically ill in the intensive care unit with an IV line and an infection or inflammation. It may help reduce the risk of blood clots without causing excess bleeding.
This trial compares two types of blood thinners (vitamin K antagonists and factor Xa inhibitors) versus no blood thinner in people with atrial fibrillation who are on dialysis or have very advanced kidney disease. It aims to see which option is safest and most effective for preventing strokes and bleeds.
This trial tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with a kidney condition called membranous nephropathy who have low albumin levels and are at high risk for clots.
Hear when a new Thromboprophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.